跳至主要内容
临床试验/ACTRN12621001210864
ACTRN12621001210864尚未招募未知

Effect of coffee consumption on hepatic steatosis in non-alcoholic fatty liver disease: a randomised controlled trial

Austin Health0 个研究点目标入组 150 人开始时间: 2021年9月10日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
Austin Health
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • Patients with a diagnosis of NAFLD with evidence of hepatic steatosis on liver ultrasound and/or Fibroscan CAP score of >260 dB/m and abnormal liver function tests.
  • Patients who are non-coffee drinkers or irregular coffee drinkers.

排除标准

  • 1. Patients who regularly consume coffee
  • 2. Patients with causes of liver disease other than NAFLD
  • 3. Alcohol intake greater than 1 (female) or 2 (male) standard drinks per day
  • 4. Patients with poorly controlled diabetes (i.e. HbA1c >9.5%)
  • 5. Patients with diabetes who have had a recent change in diabetic treatment regimen within the last 3 months
  • 6. Patients who have been involved in a NAFLD trial within the last 3 months
  • 7. Patients with decompensated liver cirrhosis
  • 8. Patients who have recently been on antibiotics within the last 3 months
  • 9. Patients who are on medications known to potentially cause fatty liver
  • 10. Patients with significant change in weight (>5%) within the last 3 months
  • 11. Patients who have contraindications to MRI scanning or unable to have MRI scan for any other reason
  • 12. Patients unable to consent

研究者

发起方
Austin Health

相似试验